Hollingsworth LLP secures major defense verdict for client Novartis in federal Aredia®/Zometa® trial.
news | May 25, 2011
After less than five hours of deliberation, a Brooklyn, New York federal jury on May 25, 2011, returned a verdict in favor of Novartis Pharmaceuticals Corporation in a seven-day trial involving Aredia® and Zometa®, bisphosphonate drugs given to people whose cancer has metastasized to their bones.
Hogan v. Novartis arises from the Aredia® and Zometa® multi-district litigation pending in the Middle District of Tennessee and the first federal trial involving a multiple myeloma plaintiff who had been prescribed Zometa® to prevent skeletal-related events, such as bone fractures, due to his underlying multiple myeloma. Plaintiff Karlene Hogan alleged that her late husband, Timothy Hogan, developed osteonecrosis of the jaw (ONJ) as a result of his receiving Zometa®.
Novartis was represented by Robert E. Johnston of Hollingsworth LLP.
The case is Hogan v. Novartis Pharm. Corp., 1:06-CV-00260-BMC-RLM (E.D.N.Y.).